欧盟监管机构正式批准默沙东(Merck)研发的Enflonsia™(Clesrovimab)上市,该药物专为预防婴幼儿在首个呼吸道合胞病毒(RSV)流行季期间发生的下呼吸道疾病而设计。这一授权标志着针对婴幼儿RSV感染预防领域的重要突破,为易感人群提供了新的免疫保护方案。
欧盟监管机构正式批准默沙东(Merck)研发的Enflonsia™(Clesrovimab)上市,该药物专为预防婴幼儿在首个呼吸道合胞病毒(RSV)流行季期间发生的下呼吸道疾病而设计。这一授权标志着针对婴幼儿RSV感染预防领域的重要突破,为易感人群提供了新的免疫保护方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.